Blepharitis is one of the most common eyelid margin disorders encountered in clinical practice. The condition encompasses a spectrum of chronic and often relapsing inflammatory processes affecting the eyelid margin, lashes, ocular surface, and meibomian glands.
In a 2009 US survey of eyecare providers, signs of blepharitis were reported in approximately 37 to 47% of patients evaluated in clinical settings.1
Blepharitis is frequently multifactorial and commonly overlaps with dry eye disease. As a result, successful management depends less on assigning a broad diagnostic label and more on identifying the dominant pathophysiologic driver guiding inflammation.
Differentiating blepharitis subtypes
Blepharitis is classically divided into anterior and posterior subtypes.
Anterior blepharitis involves the lash follicles and anterior lid margin and is commonly associated with bacterial colonization, seborrheic dermatitis, and biofilm formation. Posterior blepharitis reflects meibomian gland dysfunction (MGD) and is characterized by obstruction or qualitative alteration of meibum.2 Altered lipid secretion destabilizes the tear film and promotes evaporative dry eye.
In practice, blepharitis is rarely driven by a single mechanism. Bacterial, dermatologic, glandular, and parasitic contributors frequently coexist, resulting in chronic and relapsing inflammation. Demodex blepharitis represents an increasingly recognized component of this spectrum and may overlap with either anterior or posterior disease.
Identifying the dominant mechanism guides targeted therapy.
Download the cheat sheet here!
Blepharitis Differential Diagnosis Cheat Sheet
Use this cheat sheet with a comparative table, slit lamp images, and key clinical characteristics of blepharitis types to aid in correctly diagnosing and managing the underlying mechanism(s).
Clinical clues to the dominant mechanism
Patients with blepharitis commonly report burning, itching, tearing, fluctuating vision, and crusting on awakening. Fluctuating vision often reflects tear film instability from posterior blepharitis/MGD, and itching may suggest Demodex infestation or allergic disease.2
Crusting and eyelash debris tends to support anterior involvement. Collarettes at the lash base are pathognomonic for Demodex blepharitis. Lid margin telangiectasia, posterior margin thickening, capped meibomian gland orifices, and thickened or turbid meibum suggest posterior blepharitis/MGD.
Diagnostic pearl: Tear breakup time and ocular surface staining help assess ocular surface involvement, meibography may be useful when structural gland loss is suspected.
Anterior blepharitis
Anterior blepharitis affects the lash follicles and anterior lid margin and is most commonly associated with staphylococcal bacterial colonization or seborrheic dermatitis.2 Patients typically report eyelid irritation, burning, and crusting of the lashes on awakening, with symptoms that often fluctuate through periods of remission and exacerbation.
Slit-lamp findings may include lash debris, scaling along the lashes, and lid margin hyperemia. In more chronic or severe disease, findings may include lid margin telangiectasia, ulceration, madarosis, or trichiasis. Recurrent external hordeola may also occur in patients with chronic staphylococcal lid margin disease.
Staphylococcal blepharitis
Staphylococcal blepharitis may show the greatest response to treatment with topical antibiotic ointment following lid hygiene. Lid hygiene remains first-line therapy and is directed at reducing debris and biofilm along the anterior lid margin. Options include warm compresses, gentle lid scrubs or commercially available lid wipes, and hypochlorous acid sprays, which help reduce eyelid bacterial load.2
Commonly prescribed antibiotic ointments include erythromycin or bacitracin applied to the lid margin for 4 to 8 weeks depending on clinical severity. Recalcitrant cases may require longer courses of therapy to achieve symptom control.2 Seborrheic blepharitis often improves with lid hygiene and treatment of the associated dermatologic condition.
Demodex blepharitis
Demodex blepharitis is primarily associated with two species of mites: Demodex folliculorum and Demodex brevis. D. folliculorum inhabits eyelash follicles, whereas D. brevis resides deeper within sebaceous and meibomian glands.2,3
These mites are common commensal organisms on human skin; however, overpopulation may contribute to lid margin inflammation through mechanical follicular irritation, bacterial vectoring, and host inflammatory responses.2 Accumulation of mite debris, keratin, and lipids at the lash base produces the characteristic collarettes, or cylindrical dandruff, seen clinically.
The pathogenic contribution is multifactorial. Mites may cause direct epithelial disruption, act as bacterial vectors, and provoke hypersensitivity reactions.3 Emerging evidence also suggests structural implications beyond surface irritation.
In a retrospective analysis of approximately 400 adult patients with MGD, increasing collarette severity correlated with worse meibum quality and greater meibomian gland atrophy even after adjusting for age.4
These findings suggest Demodex infestation may contribute to progressive gland dysfunction rather than representing a purely anterior phenomenon. Recurrent internal hordeola and chalazia have also been associated with Demodex infestation.
Learn more about this study from one of the authors in the article How Demodex Blepharitis Affects Meibomian Gland Structure and Function!
Short on time? Download the Blepharitis Differential Diagnosis Cheat Sheet!
Targeted therapies for Demodex blepharitis
Collarettes at the lash base are pathognomonic for Demodex blepharitis and indicate active mite overpopulation.2 Conventional lid hygiene may reduce debris and biofilm but does not reliably eradicate mites or interrupt the inflammatory cascade associated with infestation.
Currently approved therapy
In July 2023, lotilaner ophthalmic solution 0.25% (Tarsus Pharmaceuticals) became the first FDA-approved therapy specifically indicated for the treatment of Demodex blepharitis.
In the SATURN-1 and SATURN-2 randomized controlled trials, collarette cure (defined as ≤2 collarettes per upper lid) was achieved in approximately 44 to 56% of treated eyes compared with 7 to 13% in vehicle groups at Day 43.5,6
Mite eradication (0 mites per lash) occurred in approximately 51 to 68% of treated patients versus 14% to 18% in controls. Significant improvement in lid margin erythema was also observed.5,6 These trials provide the highest level of evidence currently available for targeted mite eradication.
Established and traditional therapies
Prior to lotilaner, tea tree oil (TTO)-based lid hygiene regimens were widely used to reduce mite burden. Terpinen-4-ol (T4O), the active component, demonstrates acaricidal activity in vitro.
Clinical response depends on concentration and repeated application, and ocular surface irritation may limit tolerability. Sustained eradication has been inconsistent across studies.2
Evolving therapies
Off-label use of topical ivermectin 1% cream has been described for the treatment of Demodex blepharitis. In the clinical studies evaluating ocular Demodex, ivermectin was typically applied directly to the eyelid margin/lash base, where Demodex mites and collarettes are concentrated.7,8
Prospective and retrospective case series report reductions in collarettes and improvement in lid margin inflammation following lash-base application.7,8 Larger randomized controlled trials are needed to establish optimal dosing frequency and duration.9
Because Demodex blepharitis can overlap with rosacea, addressing facial Demodex overgrowth may be helpful in selected patients with facial erythema or papulopustular rosacea. Topical ivermectin applied to facial skin may reduce the broader Demodex burden, and dermatology coordination may be useful when facial disease is clinically significant.9
Intense pulsed light (IPL), primarily used in the management of meibomian gland dysfunction and ocular rosacea, may improve lid margin inflammation and meibomian gland function in selected patients. Proposed mechanisms include vascular coagulation and reduction of periocular inflammation.10
Because Demodex infestation frequently coexists with meibomian gland dysfunction, concurrent management of posterior disease is often required.
Posterior blepharitis and meibomian gland dysfunction
Clinical findings include capped gland orifices, turbid or inspissated meibum on expression, lid margin telangiectasia, eyelid margin thickening, foamy tear film, and reduced tear breakup time. Because Demodex blepharitis frequently overlaps with MGD, collarettes at the lash base should raise suspicion for concurrent mite infestation.2
Obstruction is commonly associated with ductal hyperkeratinization and increased meibum viscosity.2 Retained secretions promote bacterial lipase activity, altering lipid composition and increasing free fatty acids. These changes destabilize the tear film and accelerate evaporation, contributing to evaporative dry eye.3
Chronic obstruction increases intraglandular pressure and may lead to gland shortening and atrophy visible on meibography. Once structural gland loss occurs, regeneration is unlikely.
Management of posterior blepharitis
Early disease may respond to warm compresses and lid massage to improve gland outflow. In moderate cases, anti-inflammatory therapy is often required.
Oral doxycycline at sub-antimicrobial dosing reduces matrix metalloproteinase activity and bacterial lipase production, improving meibum quality; however, systemic use may be limited by gastrointestinal tolerability, microbiome disruption, and concerns about longer-term antibiotic exposure.2
Topical azithromycin ophthalmic solution 1% (AzaSite) has been studied as an off-label drop regimen for MGD/posterior blepharitis, with reported improvement in clinical signs, symptoms, and meibomian gland secretion quality.11 Short-term topical corticosteroids may be used during inflammatory flares with appropriate monitoring.
Perfluorohexyloctane ophthalmic solution (MIEBO, Bausch+Lomb) was approved in May 2023 for the treatment of signs and symptoms of dry eye disease. While it does not directly relieve meibomian gland obstruction, phase 3 trials of the drop in dry eye disease associated with MGD demonstrated significant improvement in dry eye signs and symptoms compared with hypotonic saline control, supporting its role in patients with MGD-associated evaporative dry eye.12,13
In-office and device-based therapies for blepharitis
When conventional medical therapy provides incomplete relief, in-office procedural interventions may offer additional benefit.
Lid margin debridement and microblepharoexfoliation involve mechanical removal of bacterial biofilm, keratinized debris, scurf, and collarettes from the lid margin and lash base. Examples include electromechanical microblepharoexfoliation systems such as BlephEx and manual lid margin debridement/scaling.14
Thermal-based therapies, including thermal pulsation systems such as LipiFlow, TearCare, and iLux, apply controlled heat to help liquefy inspissated meibum and improve meibomian gland outflow, often with manual or device-assisted gland expression.15
Radiofrequency treatments may also be used as heat-based therapy for MGD, although clinical evidence is still emerging and is often studied in combination with IPL.16 Moreover, IPL may improve lid margin inflammation and gland function in selected patients, particularly those with ocular rosacea or vascular lid margin disease.10
Selection of procedural therapy should be guided by the dominant inflammatory driver—biofilm, gland obstruction, vascular inflammation, or mite overpopulation.
Atopic blepharoconjunctivitis
Atopic blepharoconjunctivitis (ABC) is a chronic inflammatory disorder associated with systemic atopy. Unlike routine anterior blepharitis, ABC often involves eyelid skin, conjunctiva, and cornea.2 Patients may demonstrate periocular eczema, papillary conjunctival reaction, and corneal staining or scarring.
Management requires anti-inflammatory control rather than hygiene alone. Failure to recognize ABC can lead to progressive ocular surface damage.2
Masqueraders and red flags
Blepharitis should improve with mechanism-based therapy. Lack of response, asymmetric or progressive findings, cicatricial change, focal lid distortion, or recurrent unilateral inflammation should prompt reassessment for alternative or concurrent disease.
Several conditions may mimic blepharitis or coexist with chronic lid margin inflammation, including:2
- Ocular rosacea
- Allergic contact dermatitis
- Atopic blepharoconjunctivitis
- Ocular cicatricial pemphigoid
- Eyelid malignancy
Conclusion
Blepharitis is a multifactorial, chronic inflammatory disorder of the eyelid margin. Accurate differentiation, particularly identifying Demodex infestation and concurrent meibomian gland dysfunction, guides targeted therapy and may reduce progression to structural gland loss.
Successful management depends on careful examination, mechanism-based treatment, and patient education regarding long-term maintenance.
